glp-1 lawsuit in dallas compounder spotlights rising telehealth exclusivity wars DallasLatesNews: Dallas is projected to
Description
Show your support for accessible healthcare and medical innovation.
While these drugs offer significant preoperative weight loss benefits, their impact on surgical outcomes, tissue healing, and perioperative complications remains unclear
As the number of diabetic patien...
Clinical trials show retatrutide, Eli Lilly's new triple-agonist drug, delivered 24.2% weight loss in 48 weeks and the improvement of other conditions in longer studies.
Strategic planning must reflect this new standard of care
